Jeff Lewis
Sun, April 12, 2026 astatine 4:18 PM CDT 1 min read
Biohaven Ltd. (NYSE:BHVN) is 1 of the
On March 19, 2026, Biohaven Ltd. (NYSE:BHVN) announced completion of enrollment successful a Phase 2 proof-of-concept survey for taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed astatine value nonaccomplishment successful obesity, with topline information expected successful the 2nd fractional of 2026.
Copyright: iggyphoto / 123RF Stock Photo
Earlier successful March, Goldman Sachs raised its terms people connected Biohaven Ltd. (NYSE:BHVN) to $27 from $24 and maintained a Buy rating, citing affirmative Phase 3 results from Xenon’s azetukalner successful focal onset seizures and viewing the information arsenic supportive for the broader Kv7 class, including Biohaven’s opakalim.
Biohaven Ltd. (NYSE:BHVN) develops therapies crossed immunology, neuroscience, and oncology.
While we admit the imaginable of BHVN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey connected Google News.

1 week ago
7




English (CA) ·
English (US) ·
Spanish (MX) ·